Congenix completed phase II study of a novel drug in patients with psoriasis. 9 investigational sites in Moscow, St. Petersburg, Smolensk, Yekaterinburg and other regions of Russia demonstrated fast patient’s enrollment recruiting 119 patients within a period of less than 2 months. The rate of screening failure was less than 10%.
